Skip to main content
Equibles
NRXP logo

NRXP · NRX Pharmaceuticals, Inc. · Analyst Estimates

Track NRXP — free

Use NRXP with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research NRXP.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$3.40 +0.00 (+0.00%) At close · Sep 11
Rebalance outlook locked
Going-concern doubt — flagged Aug 14, 2026

Substantial doubt about the company's ability to continue as a going concern.

“the Company has concluded that substantial doubt exists about the Company's ability to continue as a going concern for a period of at least twelve months from the date of issuance of these consolidated financial statements.”
View the 10-Q filed Aug 14, 2026
Market Cap
$147.21M
Shares
43.30M

Analyst Estimates

Compare analyst forecasts for NRX Pharmaceuticals, Inc. across metrics and forecast periods.

Estimates are grouped by forecast period, with low, average and high together. A dash means that statistic is not available.

Only independently verified consensus published through the company's investor-relations sources is available.

Consensus not yet available

Only independently verified consensus published through the company's investor-relations sources is available.

Key facts CIK 1719406 CUSIP 629444209 13F (30d) 18 filings 18 filers Visit website Investor relations